Long intergenic non-protein coding RNA 839 (LINC00839)

Long intergenic non-protein coding RNA 839 (LINC00839) is a human long non-coding RNA (lncRNA) located on chromosome 10 and transcribed in the forward strand[3][7]. LINC00839 does not encode a protein but exerts regulatory functions, mainly in cancer biology. It is widely upregulated in several tumor types (osteosarcoma, lung adenocarcinoma, liver cancer, colorectal cancer, neuroblastoma, and nasopharyngeal carcinoma)[1][2][4][6][8]. Functionally, LINC00839 promotes malignant characteristics such as cell proliferation, migration, invasion, and metabolic reprogramming, often by acting as a microRNA sponge or interacting with regulatory proteins in the nucleus or cytoplasm. It contributes to the activation of oncogenic pathways, such as the NF-κB axis and the c-Met pathway, and modulates key cellular behaviors associated with tumor progression and metastasis[2][4]. LINC00839 is considered both as a putative therapeutic target and a biomarker candidate for cancer prognosis and therapy-monitoring, though no drugs are yet directly targeting it in clinical use[4].

Other names

LINC00839

Acts as a competitive endogenous RNA (ceRNA) by sponging microRNAs such as miR-454-3p and miR-17-5p, thereby de-repressing targets like c-Met and TLR4[1][2][4]. Binds proteins such as PTBP1 to regulate nuclear translocation of NF-κB p65 and thus modulate transcription of target genes[2]. Interacts with proteins involved in metabolism and RNA transport (e.g., FMNL2 in hepatocellular carcinoma)[6]. Regulates cellular signaling pathways including NF-κB and TLR4/NF-κB axes[2].